8/106 sources · 5 publishersUpdated Oct 30, 06:23 UTC
Penumbra posts Q3 2026 revenue growth as Boston Scientific acquisition remains pending
Penumbra reported third‑quarter 2026 revenue of $410.15 million, up 15.6% year‑over‑year, and net income of $42.28 million, yielding GAAP EPS of $1.07. Gross profit margin improved to 68.3%. The company will not give full‑year guidance because its acquisition by Boston Scientific is still pending, with the deal expected to close in early 2027.
Why it matters
The lack of full‑year guidance leaves investors without a near‑term earnings outlook (the company says it will not provide guidance due to the pending acquisition)【1】. The pending Boston Scientific deal could affect Penumbra’s valuation and future cash‑flow expectations.
Key facts
- 1Revenue of $410.15 million in Q3 2026, a 15.6% increase YoY tradingview.com
- 2Net income of $42.28 million in Q3 2026 tradingview.com
- 3GAAP EPS of $1.07 in Q3 2026 tradingview.com
- 4Gross profit margin of 68.3% in Q3 2026 prnewswire.com
- 5Acquisition by Boston Scientific pending, expected to close in early 2027 tradingview.com
- 6Company will not provide full‑year 2026 guidance due to the pending acquisition prnewswire.com
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.